NEUPNasdaqPharmaceutical PreparationsFiscal year ends June 30

Neuphoria Therapeutics Inc.

Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 18, 2026

$3.31+0.01 (+0.30%)

Close on Oct 19, 2026

Market cap: $17.90M
P/E (TTM): –
Dividend yield: –

Earnings

Quarterly results announced on Form 8-K, Item 2.02

Quarter	Reported	Time	Revenue	EPS (GAAP)	EPS (adjusted)
Q3 FY2025 Ended Mar 31, 2025	May 20, 2025	After market close	–	–	–

Press releases

Announcements Neuphoria Therapeutics filed with the SEC

Jul 23, 2026, 6:37 PM ET
PRESS RELEASE, DATED AS OF JULY 23, 2026
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Jul 23, 2026, 6:37 PM ET
INVESTOR PRESENTATION OF SCANCELL HOLDINGS PLC, DATED JULY 2026
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
Oct 27, 2025, 4:19 PM ET
PRESS RELEASE DATED OCTOBER 27, 2025
Material agreement · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Oct 20, 2025, 4:15 PM ET
PRESS RELEASE, DATED OCTOBER 20, 2025
Other events · EX-99.1 to Form 8-K
May 20, 2025, 4:15 PM ET
PRESS RELEASE DATED MAY 20, 2025
Results of operations · EX-99.1 to Form 8-K
Dec 23, 2024, 5:14 PM ET
The following description of the capital stock of Neuphoria Therapeutics
Material agreement · Listing notice · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Dec 23, 2024, 5:14 PM ET
PRESS RELEASE, DATED DECEMBER 23, 2024
Material agreement · Listing notice · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Other events · EX-99.2 to Form 8-K
Dec 16, 2024, 4:46 PM ET
PRESS RELEASE, DATED DECEMBER 16, 2024, ISSUED BY BIONOMICS LIMITED
Other events · EX-99.1 to Form 8-K
Nov 8, 2024, 4:30 PM ET
AMENDING AGREEMENT TO SCHEME IMPLEMENTATION AGREEMENT, DATED OCTOBER 24, 2024, BETWEEN BIONOMICS LIMITED AND NEUPHORIA THERAPEUTICS INC
Other events · EX-99.1 to Form 8-K
Nov 8, 2024, 4:30 PM ET
SCHEME BOOKLET, DATED NOVEMBER 8, 2024
Other events · EX-99.2 to Form 8-K
Nov 8, 2024, 4:30 PM ET
PRESS RELEASE, DATED NOVEMBER 8, 2024, ISSUED BY BIONOMICS LIMITED
Other events · EX-99.3 to Form 8-K
Jun 3, 2024, 5:18 PM ET
A. The Company and each Investor is executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by Section 4(a)(2) of the 1933 Act (as defined below);
EX-99.1 to Form 6-K
Jun 3, 2024, 5:18 PM ET
The parties hereby agree as follows:
EX-99.2 to Form 6-K
Jun 3, 2024, 5:18 PM ET
PRE-FUNDED WARRANT TO PURCHASE ADSs
EX-99.3 to Form 6-K
Mar 15, 2024, 6:06 AM ET
Hal f-Year Report – 31 December 2023
EX-99.1 to Form 6-K
Nov 30, 2023, 6:02 AM ET
Results of Annual General Meeting
EX-99.1 to Form 6-K
Nov 28, 2023, 6:03 AM ET
Bionomics Announces Retirement of Board Member
EX-99.1 to Form 6-K
Nov 3, 2023, 6:03 AM ET
Notice of Annual General Meeting Explanatory Statement and Proxy Form
EX-99.1 to Form 6-K
Oct 16, 2023, 6:03 AM ET
Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA and Solidifies Plans to Initiate the Registrational Program for BNC210 in Social Anxiety Disorder
EX-99.1 to Form 6-K
Sep 29, 2023, 6:04 AM ET
The following persons were Directors of Bionomics Limited during the period and up to the date of this report:
EX-99.1 to Form 6-K
Sep 28, 2023, 7:00 AM ET
Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)
EX-99.1 to Form 6-K
Jul 31, 2023, 6:01 AM ET
Quarterly Activities and Cashflow Report
EX-99.1 to Form 6-K
Jul 28, 2023, 6:01 AM ET
Shareholder communication on the De-listing process
EX-99.1 to Form 6-K
Jul 28, 2023, 6:01 AM ET
Bionomics Limited (ASX: BNO, Nasdaq: BNOX) – Voluntary delisting from the ASX
EX-99.2 to Form 6-K
Jul 25, 2023, 6:02 AM ET
Bionomics Limited (ASX:BNO, NASDAQ:BNOX) ( Bionomics or the Company ) announces its intention to de-list from the Australian Securities Exchange.
EX-99.1 to Form 6-K
Jul 24, 2023, 6:01 AM ET
Bionomics Limited (ASX:BNO) ( Bionomics or Company ), a clinical-stage biopharmaceutical company, requests an immediate halt to the trading of the Company’s securities quoted on the Australian Securities Exchange ( ASX ) in accordance with the ASX Listing Rule 17.1.
EX-99.1 to Form 6-K
Jul 7, 2023, 9:59 AM ET
Notification of cessation of +securities
EX-99.1 to Form 6-K
Jul 7, 2023, 6:01 AM ET
Quarterly Activities and Cashflow Report
EX-99.1 to Form 6-K
Jul 3, 2023, 6:02 AM ET
Bionomics Announces Key Leadership Updates to Drive U.S.-Focused Transformation and
EX-99.1 to Form 6-K
Apr 27, 2023, 6:02 AM ET
BIONOMICS ANNOUNCES THE COMPLETION OF ENROLMENT IN PHASE 2B ATTUNE CLINICAL TRIAL OF BNC210 IN PATIENTS WITH POST-TRAUMATIC STRESS DISORDER (PTSD)
EX-99 to Form 6-K
Mar 9, 2023, 6:05 AM ET
Bionomics Reports Promising Update on Analysis from PREVAIL Phase 2 Study of BNC210 Social Anxiety Disorder (SAD)
EX-99 to Form 6-K
Feb 23, 2023, 6:05 AM ET
Change of Director’s Interest Notice
EX-99 to Form 6-K
Feb 23, 2023, 6:05 AM ET
Change of Director’s Interest Notice
EX-99#2 to Form 6-K
Feb 23, 2023, 6:02 AM ET
Lodged with the ASX under Listing Rule 4.2A
EX-99 to Form 6-K
Feb 21, 2023, 6:02 AM ET
ASX Market Announcements ASX Limited
EX-99 to Form 6-K
Jan 30, 2023, 6:02 AM ET
Quarterly Activities and Cashflow Report
EX-99.1 to Form 6-K
Jan 18, 2023, 6:03 AM ET
Explanatory Statement and Proxy Form
EX-99.1 to Form 6-K
Jan 9, 2023, 6:10 AM ET
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.
EX-99.1 to Form 6-K
Jan 9, 2023, 6:10 AM ET
Notification of cessation of +securities
EX-99.2 to Form 6-K
Dec 19, 2022, 6:02 AM ET
Bionomics Reports Topline Results in PREVAIL Phase 2 Study of BNC210 in Social Anxiety Disorder
EX-99.1 to Form 6-K

Where these numbers come from

Parsed from the XBRL in Neuphoria Therapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-2160 reverse split on Feb 14, 2025
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is NEUP.

Revenue growth-92.5% · median -14.0%

Operating margin-1401.1% · median -986.8%

Net margin-1145.7% · median -702.1%

Company	Revenue	Growth
VTGN	$2.50M	–
KRSA	$1.90M	-12.6%
NEUP	$1.17M	-92.5%
IGC	$1.12M	-15.4%
DNTH	–	–
ATXI	–	–

Company

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: June 30
Employees: 7
Held by institutions: 36.8%
Auditor: Wolf & Company P.C.
SEC CIK: 1191070

Advertisement
300 × 250